1. GlaxoSmithKline has stopped phase III clinical trials on a cancer immunotherapeutic drug after analysis showed they may not be able to find a subpopulation of patients that would benefit from the drug.
2. Forty percent of the largest pharmaceutical companies have a board member serving in a leadership position at an academic medical center.
3. Gilead’s Sovaldi, a Hepatitis C treatment drug, is on track to have one of the highest grossing first year sales for a new drug. Sales could potentially reach $9 billion in its first year.
4. Baxter announced plans to create two separate, independent global healthcare companies focusing on biopharmaceuticals and life-saving medical products.
5. Shire Pharmaceuticals has recalled three lots of VPRIV, a long-term intravenous enzyme replacement therapy for patients with type 1 Gaucher disease, due to stainless steel and barium sulfate particulate matter found in a few vials.
6. The manufacturer of OxyContin, Purdue Pharma, has developed a tamper-resistant hydrocodone drug that prevents users from altering the drug for misuse or abuse.
7. Teva Pharmaceuticals faces a $27.6 million settlement to resolve False Claims Act allegations accusing the company of paying kickbacks to a physician to prescribe the company’s anti-psychotic drug.
8. Pharmaceutical companies are scaling back payments to healthcare professionals who promote their drugs.
More Articles on Supply Chain:
FDA Clears Intuitive Surgical’s Latest da Vinci Robot Upgrade
Steris to Acquire Integrated Medical Systems for $165M
6 Alternatives to Ease the Nitroglycerin Shortage
